Ensysce Biosciences is developing chemically engineered drug platforms—TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance)—to reduce abuse and oral overdose risk for opioid therapies. Its lead candidate, PF614-MPAR, combines the PF614 opioid prodrug (activated by trypsin in the small intestine) with an MPAR mechanism intended to limit opioid release when excessive pills are ingested. PF614-MPAR has received Breakthrough Therapy designation from the FDA following initial clinical data from the PF614-101 study. Ensysce is initially developing PF614-MPAR for patients with severe pain and believes its approach could create a new class of opioids that maintain therapeutic exposure during prescribed use while restricting excess exposure during misuse. The company is exploring additional applications of its platforms for amphetamines and methadone. PF614-MPAR remains investigational and has not been approved by the FDA; additional studies are required to establish safety and effectiveness.

Total raised

$72M

Funding rounds

5

Latest round

Grant

Latest activity

Jul 2026